Tociliuzumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).
It is very uncertain whether tociliuzumab changes clinical improvement D60 or moref compared with standard care/placebo (very low certainty).
Tociliuzumab showed no clear difference in WHO progression score (level 7 or above) D28 compared with standard care/placebo (low certainty).
Tociliuzumab leads to lower all‐cause mortality D28 compared with standard care/placebo (high certainty).
Tociliuzumab showed no clear difference in all‐cause mortality D60 or more compared with standard care/placebo (low certainty).
Tociliuzumab showed no clear difference in adverse events ( compared with standard care/placebo (moderate certainty).
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).